GlassScriptPhysician profile
Julia Menetrey
NPI 1518295435
$10,460.21
in general payments reported to CMS, 2019-2025
34 companies · $2,013 in 2025
The $2,013 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,175 · 2022: $2,892 · 2023: $1,564 · 2024: $816 · 2025: $2,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277 · Travel and Lodging: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.22 |
| Travel and Lodging | $1,115.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,158.28 | 2021-2025 | Watchman Access System, Watchman |
| Novartis Pharmaceuticals Corporation | $1,584.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $847.16 | 2021-2025 | Farxiga, Wainua |
| Amgen INC. | $776.95 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $706.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $515.07 | 2021-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $503.05 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $448.01 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $373.00 | 2021-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $354.25 | 2021-2024 | Camzyos, Eliquis |
| Atricure, INC. | $334.52 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $235.49 | 2021-2023 | Opsumit |
| Pfizer INC. | $220.79 | 2022-2023 | |
| Amarin Pharma, INC. | $214.54 | 2021-2022 | |
| Esperion Therapeutics, INC. | $206.24 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $195.58 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Scpharmaceuticals INC. | $117.74 | 2023-2025 | |
| Chiesi USA, INC. | $103.79 | 2021-2022 | |
| Daiichi Sankyo INC. | $80.06 | 2021-2022 | |
| Novo Nordisk INC | $65.40 | 2023-2025 | Ozempic, Wegovy |
| Vifor Pharma, INC. | $57.51 | 2021 | |
| United Therapeutics Corporation | $52.66 | 2022 | |
| Baxter Healthcare | $49.30 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Abbvie INC. | $47.04 | 2021 | |
| Heartflow, INC. | $36.19 | 2024-2025 | |
| Bardy Diagnostics, INC. | $33.96 | 2021-2022 | |
| Cvrx, INC. | $23.81 | 2022-2023 | Barostim Neo System |
| Lilly USA, LLC | $23.49 | 2024 | Zepbound |
| Irhythm Technologies, INC. | $21.08 | 2023 | Zio Xt Patch |
| Philips North America LLC | $16.74 | 2024 | (Ck7) Extended Holter |
| Abiomed | $15.80 | 2025 | |
| Edwards Lifesciences Corporation | $15.41 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $14.33 | 2023 | Inpefa |
| Takeda Pharmaceuticals U.S.A., INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Menetrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.